menu
    • menu

    Company profile for Merck & Co

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-05-19

    Virtual Booth

    Contact Supplier

    Chirogate is a professional Prostaglandin manufacturer.

    Virtual Booth

    Contact Supplier

    Temad- We think of world-class quality.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-04-28

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    SERVICES

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Our goal is to lead the way to a healthier future. But we also care about how we get there together. As a company whose products touch the lives and well being of people around the world, we hold ourselves to a high standard. And we expect others to hold us to that same high standard. We believe in operating openly, honestly and with the highest degree of ethics and integrity. This includes: making sure that the compa...
    Our goal is to lead the way to a healthier future. But we also care about how we get there together. As a company whose products touch the lives and well being of people around the world, we hold ourselves to a high standard. And we expect others to hold us to that same high standard. We believe in operating openly, honestly and with the highest degree of ethics and integrity. This includes: making sure that the company complies with all applicable laws and regulations globally.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Merck & CoUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    One Merck Drive, P.O. Box 100 Whitehouse Station, NJ 08889-0100
    Telephone
    Telephone
    +1 732 422 7800
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.merck.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI North America

    Not Confirmed

    envelop Contact Supplier

    CPhI North America

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    Alchem NicSelect™ grants customers royalty-free access to T-MAX™ tech for 3-in-1 vape satisfaction in flavour-restricted markets

    micAlchem NicSelect™ grants customers royalty-free access to T-MAX™ tech for 3-in-1 vape satisfaction in flavour-restricted markets

    With increasing flavour bans in key markets, vaping brands are facing significant challenges in providing satisfying alternatives to vapers and smokers looking to transition. Recognising this need, Alchem NicSelect™ is making a bold move by offering its key customers royalty-free and unrestricted geographical access to its revolutionary T-MAX™ technology.“At Alchem NicSelect™, we understand the urgency for vaping brands to adapt to new regulations without compromising on satisfaction. By offering royalty-free access to T-MAX™ technology, we empower our customers to provide the closest cigarette-like experience possible, even in markets with strict flavour restrictions,” said Riccardo Santambrogio, Europe Sales Manager.HIGHLIGHTS// offering royalty-free access to T-MAX™ technology/ unrestricted geographical access/ closest cigarette-like experience Addressing the biggest barrier: Nicotine satisfactionOne of the primary reasons many vapers are dissatisfied and smokers struggle to switch to vaping is that traditional nicotine solutions fail to replicate the rapid satisfaction provided by cigarettes. Nicotine replacement therapies (NRTs) and even conventional vaping products often lack the immediate nicotine hit, throat feel, and overall experience that smokers are accustomed to. T-MAX™ solves this problem by engineering a nicotine experience that closely mimics cigarette consumption without relying on flavours.T-MAX™ provides a unique 3-in-1 approach:1. The Speed of a Cigarette – Rapid nicotine delivery and rush within seconds for immediate satisfaction.2. The Power of Nicotine Salts – A stronger perceived nicotine effect without exceeding legal limits (20 mg/ml nicotine limit under the European Tobacco Products Directive). With T-MAX™, 8 mg/ml feels like 20 mg/ml, and 14 mg/ml feels like 40 mg/ml.3. The Throat Hit of Freebase Nicotine – Especially in a flavour-free formulation, the combined ingredients in T-MAX™ deliver an even more satisfying throat feel than expected from nicotine base, much closer to and more familiar with a cigarette throat feel that habitual smokers recognise.HIGHLIGHTS// unique 3-in-1 approach/ rush within seconds/ stronger perceived nicotine effect without exceeding legal limits/ more satisfying throat feel that habitual smokers recogniseNo flavour, but not less satisfyingWhile flavours have traditionally played a role in vaping adoption, market realities are shifting. With flavour bans spreading across regions, brands need solutions that deliver satisfaction without relying on taste. Consumer research has shown that T-MAX™ performs exceptionally well even without added flavours. Since most cigarette smokers do not smoke for the tobacco flavour but rather for the nicotine hit and habitual experience, T-MAX™ provides a viable alternative that aligns with new regulatory landscapes.HIGHLIGHTS// flavour bans spreading across regions/ T-MAX™ performs exceptionally well even without added flavoursEmpowering vape brands with free access to T-MAX™By granting customers royalty-free access to the T-MAX™ technology, Alchem NicSelect™ is removing barriers for vaping brands and original equipment manufacturers (OEMs) looking to adapt to regulatory changes. This open-access approach ensures that manufacturers can integrate T-MAX™ into their product lines without additional costs, allowing them to offer superior nicotine satisfaction in markets where flavours are no longer an option.HIGHLIGHTS// removing barriers for vaping brands and OEMs looking to adapt/ manufacturers can integrate T-MAX™ into product lines without additional costsThe future of vaping in restricted marketsWith T-MAX™, the vaping industry has a powerful tool to retain customers and convert smokers who have struggled with traditional vaping products. By delivering the key elements of cigarette satisfaction — without combustion or flavours — T-MAX™ is set to redefine what a satisfying vape experience means in a post-flavour-ban world.“Our commitment to innovation and accessibility means we are providing our customers with the solutions they need to navigate an evolving regulatory landscape. T-MAX™ allows brands to offer a highly satisfying experience that mimics smoking without relying on flavours. The message is clear: no flavour, but not less satisfying”, added Santambrogio.HIGHLIGHTS// powerful tool to retain customers and convert smokers/ delivering the key elements of cigarette satisfaction without combustion or flavours/ no flavour, but not less satisfying

    Impressions: 274

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets

    Radio Compass
    06 May 2025
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    ReelPharmaConnecting People, Mentalities & MarketsConnecting People, Mentalities & Markets

    Connecting People, Mentalities & Markets
    Connecting People, Mentalities & Markets

    reelConnecting People, Mentalities & Markets

    This PharmaReel highlights Transo-Pharm USA’s offerings of premium Phyto Cannabidiol (CBD) and Phyto Cannabigerol (CBG) isolates from its cGMP-certified facility inspected by the FDA and ANVISA. The company has an expanded reach across the US and EU.

    Impressions: 332

    read-more

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    DMF filings surge 44% in Q1 2025; India tops list with 51% rise in year-on-year submissions

    DMF filings surge 44% in Q1 2025; India tops list with 51% rise in year-on-year submissions

    The first quarter (Q1) of 2025 witnessed an impressive surge in Drug Master File (DMF) submissions to the US Food and Drug Administration (FDA), signaling a robust expansion in pharmaceutical development activities, the looming threat of tariffs notwithstanding.A total of 339 Type II DMFs were submitted during this period, as opposed to 235 submissions in Q1 2024, marking an exceptional increase of 44.26 percent. PharmaCompass’ data suggests that this is a record high for any first quarter.Overall, 440 DMFs were submitted across all categories (Types II, III, IV, and V) during Q1 2025, compared to 353 in the same period last year — representing a 24.65 percent increase.India and China continued to dominate the DMF landscape. India led with 162 submissions in Q1 2025, posting a remarkable 51.4 percent increase over 107 submissions recorded in Q1 2024. China followed with 135 submissions, representing a 33.66 percent increase over the 101 filings in Q1 2024.Taiwan sprung a surprise as a distant third. It made 12 DMF submissions in Q1 2025, as opposed to just one in Q1 2024. Western countries like the US, Spain, Germany, and Italy have maintained relatively stable or declining submission rates. Only the Netherlands showed significant growth with four DMF submissions in Q1 2025, up from zero in Q1 2024. View FDA DMF Filings in Q1 2025 (Power BI Dashboard, Free Excel Available)Indian giants MSN, Aurobindo, Cipla, Dr Reddy’s lead record-breaking DMF surgeIndia lived up to its “pharmacy of the world” reputation with the highest DMF submissions. In fact, seven of the top eight companies in the DMF tally were headquartered in India. MSN Group, emerged as the unequivocal leader with 23 submissions in Q1 2025, as against 15 in Q1 2024. Aurobindo Pharma increased its DMF activity from seven submissions in Q1 2024 to 12 in Q1 2025. Alivus Life Sciences, formerly known as Glenmark, made a dramatic leap with eight submissions in Q1 2025, quadrupling its previous year’s count of just two. Cipla more than doubled its DMF submissions — from three in Q1 2024 to eight in Q1 2025.Dr. Reddy’s Laboratories, one of India’s largest generic drugmakers, filed seven DMF submissions. The company’s Q1 2025 DMF portfolio includes high-value molecules like deucravacitinib, finerenone, enzalutamide, niraparib tosylate monohydrate, tucatinib, and tizanidine hydrochloride.Dr. Reddy’s has also indicated that they are open to manufacturing in the US. Meanwhile, Hetero Drugs filed seven submissions while Lee Pharma recorded six in Q1 2025.Chinese manufacturer Jiangsu East-Mab Biomedical Technology also established a significant presence with six DMFs. View FDA DMF Filings in Q1 2025 (Power BI Dashboard, Free Excel Available) Semaglutide, finerenone see most DMF submissions; first-time filings surge 64%Semaglutide and finerenone emerged as the most documented molecules in Q1 2025, each garnering nine DMF submissions. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that has revolutionized diabetes management and weight loss treatment, continues to attract significant manufacturer interest. Similarly, finerenone, a non-steroidal drug used in treating chronic kidney disease in type 2 diabetes patients, has garnered attention from manufacturers.Carfilzomib, used in multiple myeloma treatment, secured the third position with five DMF submissions. Deucravacitinib, a novel drug approved for moderate to severe plaque psoriasis, followed with four DMF submissions.There were several molecules with three DMF submissions each. Among them were tapinarof, a novel drug for psoriasis, and tirzepatide, a GLP-1/GIP receptor agonist that has shown remarkable efficacy in diabetes and weight management. During the quarter, 23 molecules received their inaugural DMF submissions. This number has risen by 64 percent since Q1 2024, when only 14 drugs saw their first DMF filings.In Q1 2025, these 23 first-time molecules collectively garnered 30 DMF submissions, with deucravacitinib emerging as the clear leader. Indian companies Dr. Reddy’s Laboratories and Cipla filed DMFs for this plaque psoriasis treatment as did Spain’s Curia and PMC Global.The Q1 2025 roster of first-time DMF filings include retatrutide (another GLP-1 receptor agonist), sotagliflozin, setmelanotide acetate, daridorexant, nusinersen, zavegepant, belzutifan, elacestrant dihydrochloride, selumetinib sulfate, sotorasib, atogepant, omadacycline tosylate, osilodrostat phosphate, ensifentrine, landiolol hydrochloride, maralixibat chloride, maribavir, methyl olivetolate, diazoxide choline, sparsentan, thinnertide, and vismodegib. View FDA DMF Filings in Q1 2025 (Power BI Dashboard, Free Excel Available) Our viewGiven Trump’s rhetoric around tariffs on imported drugs, the record-breaking DMF submissions in Q1 2025 sent out a strong message that the global pharmaceutical industry is willing to take on the complex geopolitical situation with resilience and strategic foresight.On a different note, the rise in DMF filings also indicate increased workload for the FDA staff, as also more inspections by the agency. It seems like more ‘laid off’ FDA employees will be asked to return to work in the coming days.
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 519

    https://www.pharmacompass.com/radio-compass-blog/dmf-filings-surge-44-in-q1-2025-india-tops-list-with-51-rise-in-year-on-year-submissions

    #PharmaFlow by PHARMACOMPASS
    15 May 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Begins
    IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Begins

    19 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250519791895/en/IDeate-Esophageal01-Phase-3-Trial-of-Ifinatamab-Deruxtecan-Initiated-in-Certain-Patients-with-Pretreated-Advanced-or-Metastatic-Esophageal-Squamous-Cell-Carcinoma

    BUSINESSWIRE
    19 May 2025
    Share Share
    Merck to Share PAH Research at ATS 2025 Conference
    Merck to Share PAH Research at ATS 2025 Conference

    16 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250515033520/en/Merck-to-Present-New-Clinical-and-Outcomes-Research-Data-at-The-American-Thoracic-Societys-ATS-2025-International-Conference-Demonstrating-Commitment-to-Advancing-Research-in-Pulmonary-Arterial-Hypertension

    BUSINESSWIRE
    16 May 2025
    Share Share
    FDA expands use of Merck's cancer drug for adrenal gland tumors
    FDA expands use of Merck's cancer drug for adrenal gland tumors

    15 May 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-expands-use-mercks-cancer-drug-adrenal-gland-tumors-2025-05-14/

    REUTERS
    15 May 2025
    Share Share
    Merck to Present Oncology Advances at ASCO 2025
    Merck to Present Oncology Advances at ASCO 2025

    13 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250513947812/en/Research-on-Novel-Treatment-Approaches-and-Scientific-Advances-From-Mercks-Broad-and-Differentiated-Oncology-Portfolio-and-Pipeline-to-be-Presented-at-ASCO-2025

    BUSINESSWIRE
    13 May 2025
    Share Share
    Dawn Health, Merck Launch Digital Ecosystem for Growth Disorders
    Dawn Health, Merck Launch Digital Ecosystem for Growth Disorders

    07 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/dawn-health-and-merck-launch-next-generation-digital-ecosystem-for-growth-disorders-302447537.html

    PR NEWSWIRE
    07 May 2025
    Share Share
    Merck to Join Bank of America 2025 Healthcare Conference
    Merck to Join Bank of America 2025 Healthcare Conference

    07 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250507530992/en/Merck-to-Participate-in-the-Bank-of-America-2025-Global-Healthcare-Conference

    BUSINESSWIRE
    07 May 2025
    Share Share

    KDMF

    read-more
    read-more

    01

    alendronate sodium hydrate

    U.S.A
    STLE Annual Meeting
    Not Confirmed
    arrow

    alendronate sodium hydrate

    U.S.A
    arrow
    STLE Annual Meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Merck & Co

    Registrant Name : Korea Organon Co., Ltd.

    Registration Date : 2022-01-05

    Registration Number : 20220105-209-J-1194

    Manufacturer Name : MSD International GmbH T/A MSD...

    Manufacturer Address : Kilsheelan, Clonmel, Co. Tipperary, Ireland

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    02

    Aprepitant

    U.S.A
    STLE Annual Meeting
    Not Confirmed
    arrow

    Aprepitant

    U.S.A
    arrow
    STLE Annual Meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Merck & Co

    Registrant Name : Korea MSD Co., Ltd.

    Registration Date : 2005-07-28

    Registration Number : No. 906-4-ND

    Manufacturer Name : MSD International GmbH (Puerto...

    Manufacturer Address : Road #2, Kilometer 56.7, Barceloneta, PR 00617

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    03

    Boceprevir

    U.S.A
    STLE Annual Meeting
    Not Confirmed
    arrow

    Boceprevir

    U.S.A
    arrow
    STLE Annual Meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Merck & Co

    Registrant Name : Korea MSD Co., Ltd.

    Registration Date : 2014-06-24

    Registration Number : Su3281-14-ND

    Manufacturer Name : MSD International GmbH

    Manufacturer Address : 50 Tuas West Drive Singapore 638408

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    04

    Desloratadine

    U.S.A
    STLE Annual Meeting
    Not Confirmed
    arrow

    Desloratadine

    U.S.A
    arrow
    STLE Annual Meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Merck & Co

    Registrant Name : Korea MSD Co., Ltd.

    Registration Date : 2012-12-28

    Registration Number : 20121228-179-I-98-03

    Manufacturer Name : Schering-Plough (Avondale) Com...

    Manufacturer Address : Rathdrum, County Wicklow

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    05

    Desloratadine

    U.S.A
    American Thoracic Society
    Not Confirmed
    arrow

    Desloratadine

    U.S.A
    arrow
    American Thoracic Society
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Merck & Co

    Registrant Name : Korea Organon Co., Ltd.

    Registration Date : 2020-04-02

    Registration Number : 20200402-179-I-602-04

    Manufacturer Name : MSD International GmbH(Singapo...

    Manufacturer Address : 50 Tuas West Drive Singapore 638408@Polígono Malpica Calle J No. 3-450016 Zaragoza S...

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    06

    Dexketopropentromethamole

    U.S.A
    STLE Annual Meeting
    Not Confirmed
    arrow

    Dexketopropentromethamole

    U.S.A
    arrow
    STLE Annual Meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Merck & Co

    Registrant Name : Aging Life Science Co., Ltd.

    Registration Date : 2018-04-09

    Registration Number : 20160429-180-I-461-02(1)

    Manufacturer Name : Saurav Chemicals Limited@[Keto...

    Manufacturer Address : Village Bhagwanpura, Barwala Road, Derabassi, District Sahibzada Ajit Shigh Nagar, Pu...

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    07

    Doravirine

    U.S.A
    STLE Annual Meeting
    Not Confirmed
    arrow

    Doravirine

    U.S.A
    arrow
    STLE Annual Meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Merck & Co

    Registrant Name : Korea MSD Co., Ltd.

    Registration Date : 2019-11-22

    Registration Number : Su90-29-ND

    Manufacturer Name : MSD International GmbH

    Manufacturer Address : Ballydine, Kilsheelan, Co. Tipperary, Ireland

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    08

    Elbasvir

    U.S.A
    STLE Annual Meeting
    Not Confirmed
    arrow

    Elbasvir

    U.S.A
    arrow
    STLE Annual Meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Merck & Co

    Registrant Name : Korea MSD Co., Ltd.

    Registration Date : 2016-10-14

    Registration Number : Su90-17-ND

    Manufacturer Name : MSD International GmbH

    Manufacturer Address : Ballydine, Kilsheelan, Co. Tipperary, Ireland

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    09

    Ertapenem sodium

    U.S.A
    STLE Annual Meeting
    Not Confirmed
    arrow

    Ertapenem sodium

    U.S.A
    arrow
    STLE Annual Meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Cherokee Pharmaceuticals LLC

    Registrant Name : Korea MSD Co., Ltd.

    Registration Date : 2020-12-11

    Registration Number : 20201211-210-J-798

    Manufacturer Name : Cherokee Pharmaceuticals LLC

    Manufacturer Address : 100 Avenue C Riverside, PA 17868 USA

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    10

    Ezetimibe

    U.S.A
    STLE Annual Meeting
    Not Confirmed
    arrow

    Ezetimibe

    U.S.A
    arrow
    STLE Annual Meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Merck & Co

    Registrant Name : Korea Organon Co., Ltd.

    Registration Date : 2003-10-19

    Registration Number : 906-2-ND

    Manufacturer Name : MSD International GmbH (Singap...

    Manufacturer Address : 50 Tuas West Drive Singapore 638408

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Merck’s KEYNOTE-B96 Hits PFS Goal in PD-L1+ Ovarian Cancer Phase 3 Trial

    Details:

    Keytruda (pembrolizumab), anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab for platinum-resistant recurrent ovarian cancer whose tumors expressed PD-L1.


    Lead Product(s): Pembrolizumab,Paclitaxel,Bevacizumab

    Therapeutic Area: Oncology Brand Name: Keytruda

    Study Phase: Phase IIIProduct Type: Antibody

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable May 15, 2025

    blank

    01

    Merck & Co

    U.S.A
    arrow
    STLE Annual Meeting
    Not Confirmed

    Merck & Co

    U.S.A
    arrow
    STLE Annual Meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pembrolizumab,Paclitaxel,Bevacizumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Merck’s KEYNOTE-B96 Hits PFS Goal in PD-L1+ Ovarian Cancer Phase 3 Trial

    Details : Keytruda (pembrolizumab), anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab for platinum-resistant recurrent ovarian cancer whose tumors expressed PD-L1.

    Product Name : Keytruda

    Product Type : Antibody

    Upfront Cash : Inapplicable

    May 15, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    FDA Clears Merck’s WELIREG for Adults and Teens with Advanced PPGL

    Details:

    Welireg (belzutifan) is first and only HIF-2α inhibitor, being investigated for the treatment of 12 years and older with advanced, unresectable pheochromocytoma and paraganglioma (PPGL).


    Lead Product(s): Belzutifan

    Therapeutic Area: Oncology Brand Name: Welireg

    Study Phase: Approved FDFProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable May 14, 2025

    blank

    02

    Merck & Co

    U.S.A
    arrow
    STLE Annual Meeting
    Not Confirmed

    Merck & Co

    U.S.A
    arrow
    STLE Annual Meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Belzutifan

    Therapeutic Area : Oncology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    FDA Clears Merck’s WELIREG for Adults and Teens with Advanced PPGL

    Details : Welireg (belzutifan) is first and only HIF-2α inhibitor, being investigated for the treatment of 12 years and older with advanced, unresectable pheochromocytoma and paraganglioma (PPGL).

    Product Name : Welireg

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    May 14, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Merck Links up with Cyprumed in $493M Oral Peptide Deal

    Details:

    Under the licensing agreement, MSD will acquire global rights to Cyprumed's platform for developing oral formulations of its peptide therapies.


    Lead Product(s): Undisclosed

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: UndisclosedProduct Type: Peptide

    Recipient: Cyprumed

    Deal Size: $493.0 million Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement April 15, 2025

    blank

    03

    Merck & Co

    U.S.A
    arrow
    STLE Annual Meeting
    Not Confirmed

    Merck & Co

    U.S.A
    arrow
    STLE Annual Meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Oncology

    Highest Development Status : Undisclosed

    Recipient : Cyprumed

    Deal Size : $493.0 million

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Merck Links up with Cyprumed in $493M Oral Peptide Deal

    Details : Under the licensing agreement, MSD will acquire global rights to Cyprumed's platform for developing oral formulations of its peptide therapies.

    Product Name : Undisclosed

    Product Type : Peptide

    Upfront Cash : Undisclosed

    April 15, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Organon Acquires Tofidenc, A Commercialized Biosimilar to Actemr in U.S

    Details:

    Through this acquisition, Organon enhances and broadens its U.S. biosimilars portfolio, gaining commercial rights in the US for tofidence (tocilizumab), an intravenous biosimilar to actemra.


    Lead Product(s): Tocilizumab

    Therapeutic Area: Immunology Brand Name: Tofidence

    Study Phase: Approved FDFProduct Type: Antibody

    Recipient: Biogen

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Acquisition April 01, 2025

    blank

    04

    Organon

    U.S.A
    arrow
    STLE Annual Meeting
    Not Confirmed

    Organon

    U.S.A
    arrow
    STLE Annual Meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Tocilizumab

    Therapeutic Area : Immunology

    Highest Development Status : Approved FDF

    Recipient : Biogen

    Deal Size : Undisclosed

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Organon Acquires Tofidenc, A Commercialized Biosimilar to Actemr in U.S

    Details : Through this acquisition, Organon enhances and broadens its U.S. biosimilars portfolio, gaining commercial rights in the US for tofidence (tocilizumab), an intravenous biosimilar to actemra.

    Product Name : Tofidence

    Product Type : Antibody

    Upfront Cash : Undisclosed

    April 01, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Enhertu Initiated in Patients with Previously Untreated HER2 Positive Gastric Cancer

    Details:

    Enhertu (trastuzumab deruxtecan) in combination with fluoropyrimidine chemotherapy, pembrolizumab is being studied for unresectable, locally advanced or metastatic HER2 positive gastric or GEJ cancer.


    Lead Product(s): Trastuzumab Deruxtecan,Cisplatin,Pembrolizumab

    Therapeutic Area: Oncology Brand Name: Enhertu

    Study Phase: Phase IIIProduct Type: Antibody-drug Conjugate

    Recipient: Daiichi Sankyo

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 31, 2025

    blank

    05

    Merck & Co

    U.S.A
    arrow
    STLE Annual Meeting
    Not Confirmed

    Merck & Co

    U.S.A
    arrow
    STLE Annual Meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Trastuzumab Deruxtecan,Cisplatin,Pembrolizumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Recipient : Daiichi Sankyo

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Enhertu Initiated in Patients with Previously Untreated HER2 Positive Gastric Cancer

    Details : Enhertu (trastuzumab deruxtecan) in combination with fluoropyrimidine chemotherapy, pembrolizumab is being studied for unresectable, locally advanced or metastatic HER2 positive gastric or GEJ cancer.

    Product Name : Enhertu

    Product Type : Antibody-drug Conjugate

    Upfront Cash : Inapplicable

    March 31, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    EU Approves Merck's Capvaxive for Invasive Pneumococcal Disease Prevention

    Details:

    Capvaxive (21-valent Pneumococcal Conjugate Vaccine) is a prophylactic vaccine candidate which is approved for the treatment of pneumococcal pneumonia in adults.


    Lead Product(s): 21-valent Pneumococcal Conjugate Vaccine

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Capvaxive

    Study Phase: Approved FDFProduct Type: Vaccine

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 27, 2025

    blank

    06

    Merck & Co

    U.S.A
    arrow
    STLE Annual Meeting
    Not Confirmed

    Merck & Co

    U.S.A
    arrow
    STLE Annual Meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : 21-valent Pneumococcal Conjugate Vaccine

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    EU Approves Merck's Capvaxive for Invasive Pneumococcal Disease Prevention

    Details : Capvaxive (21-valent Pneumococcal Conjugate Vaccine) is a prophylactic vaccine candidate which is approved for the treatment of pneumococcal pneumonia in adults.

    Product Name : Capvaxive

    Product Type : Vaccine

    Upfront Cash : Inapplicable

    March 27, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Merck’s DOR/ISL Two-Drug Regimen Shows 48-Week HIV-1 Viral Suppression in Trials

    Details:

    MK-8591A is a combination of islatravir and Doravirine which are being investigated as non-nucleoside reverse transcriptase translocation inhibitor of HIV-1.


    Lead Product(s): Islatravir,Doravirine

    Therapeutic Area: Infections and Infectious Diseases Brand Name: MK-8591A

    Study Phase: Phase IIIProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 12, 2025

    blank

    07

    Merck & Co

    U.S.A
    arrow
    STLE Annual Meeting
    Not Confirmed

    Merck & Co

    U.S.A
    arrow
    STLE Annual Meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Islatravir,Doravirine

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Merck’s DOR/ISL Two-Drug Regimen Shows 48-Week HIV-1 Viral Suppression in Trials

    Details : MK-8591A is a combination of islatravir and Doravirine which are being investigated as non-nucleoside reverse transcriptase translocation inhibitor of HIV-1.

    Product Name : MK-8591A

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    March 12, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    FDA Grants Priority Review for Merck’s KEYTRUDA Combo

    Details:

    Keytruda (pembrolizumab) is a PD-1 inhibitor antibody, being evaluated for the treatment of Stage III-IVA resectable LA-HNSCC.


    Lead Product(s): Pembrolizumab,Cisplatin

    Therapeutic Area: Oncology Brand Name: Keytruda

    Study Phase: Phase IIIProduct Type: Antibody

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable February 25, 2025

    blank

    08

    Merck & Co

    U.S.A
    arrow
    STLE Annual Meeting
    Not Confirmed

    Merck & Co

    U.S.A
    arrow
    STLE Annual Meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pembrolizumab,Cisplatin

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    FDA Grants Priority Review for Merck’s KEYTRUDA Combo

    Details : Keytruda (pembrolizumab) is a PD-1 inhibitor antibody, being evaluated for the treatment of Stage III-IVA resectable LA-HNSCC.

    Product Name : Keytruda

    Product Type : Antibody

    Upfront Cash : Inapplicable

    February 25, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    WELIREG® (belzutifan) Receives First European Commission Approval for Two Indications

    Details:

    Welireg (belzutifan), an oral HIF-2α inhibitor, being evaluated for the treatment of adult and pediatric patients with advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.


    Lead Product(s): Belzutifan

    Therapeutic Area: Rare Diseases and Disorders Brand Name: Welireg

    Study Phase: Approved FDFProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable February 18, 2025

    blank

    09

    Merck & Co

    U.S.A
    arrow
    STLE Annual Meeting
    Not Confirmed

    Merck & Co

    U.S.A
    arrow
    STLE Annual Meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Belzutifan

    Therapeutic Area : Rare Diseases and Disorders

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    WELIREG® (belzutifan) Receives First European Commission Approval for Two Indications

    Details : Welireg (belzutifan), an oral HIF-2α inhibitor, being evaluated for the treatment of adult and pediatric patients with advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.

    Product Name : Welireg

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    February 18, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Merck Starts Phase 3 waveLINE-010 Study of Zilovertamab Vedotin in DLBCL

    Details:

    MK-2140 (zilovertamab vedotin) is an investigational ADC that targets ROR1 receptor. It is being evaluated for the treatment of previously untreated patients with diffuse large b-cell lymphoma.


    Lead Product(s): Zilovertamab Vedotin,Cyclophosphamide,Rituximab

    Therapeutic Area: Oncology Brand Name: MK-2140

    Study Phase: Phase IIProduct Type: Antibody-drug Conjugate

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable February 06, 2025

    blank

    10

    Merck & Co

    U.S.A
    arrow
    STLE Annual Meeting
    Not Confirmed

    Merck & Co

    U.S.A
    arrow
    STLE Annual Meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Zilovertamab Vedotin,Cyclophosphamide,Rituximab

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Merck Starts Phase 3 waveLINE-010 Study of Zilovertamab Vedotin in DLBCL

    Details : MK-2140 (zilovertamab vedotin) is an investigational ADC that targets ROR1 receptor. It is being evaluated for the treatment of previously untreated patients with diffuse large b-cell lymphoma.

    Product Name : MK-2140

    Product Type : Antibody-drug Conjugate

    Upfront Cash : Inapplicable

    February 06, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDA Orange Book

    read-more
    read-more

    Europe

    read-more
    read-more

    01

    Brand Name : Vaxneuvance

    U.S.A
    American Thoracic Society
    Not Confirmed
    arrow

    Brand Name : Vaxneuvance

    U.S.A
    arrow
    American Thoracic Society
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : Switzerland

    15-valent pneumococcal polysaccharide CRM conjugat...

    Merck & Co

    Dosage Form : Inj Susp

    Dosage Strength :

    Packaging :

    Brand Name : Vaxneuvance

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Switzerland

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Brand Name : Vaxneuvance

    U.S.A
    American Thoracic Society
    Not Confirmed
    arrow

    Brand Name : Vaxneuvance

    U.S.A
    arrow
    American Thoracic Society
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : Switzerland

    15-valent pneumococcal polysaccharide CRM conjugat...

    Merck & Co

    Dosage Form : Inj Susp

    Dosage Strength :

    Packaging :

    Brand Name : Vaxneuvance

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Switzerland

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Brand Name : Campral

    U.S.A
    American Thoracic Society
    Not Confirmed
    arrow

    Brand Name : Campral

    U.S.A
    arrow
    American Thoracic Society
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : Switzerland

    Acamprosatum

    Merck & Co

    Dosage Form : Film-Coated Tablets

    Dosage Strength : 300mg

    Packaging :

    Brand Name : Campral

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Switzerland

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Brand Name : Campral

    U.S.A
    American Thoracic Society
    Not Confirmed
    arrow

    Brand Name : Campral

    U.S.A
    arrow
    American Thoracic Society
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : Switzerland

    Acamprosatum

    Merck & Co

    Dosage Form : Filmtablet

    Dosage Strength : 300mg

    Packaging :

    Brand Name : Campral

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Switzerland

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Brand Name : Fosavance weekly tab...

    U.S.A
    American Thoracic Society
    Not Confirmed
    arrow

    Brand Name : Fosavance weekly tab...

    U.S.A
    arrow
    American Thoracic Society
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : Switzerland

    Acidum alendronicum; cholecalciferol (vitamin D3)

    Organon

    Dosage Form : Tabl

    Dosage Strength : 70/2800

    Packaging :

    Brand Name : Fosavance weekly tablets

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Switzerland

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Brand Name : Fosavance weekly tab...

    U.S.A
    American Thoracic Society
    Not Confirmed
    arrow

    Brand Name : Fosavance weekly tab...

    U.S.A
    arrow
    American Thoracic Society
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : Switzerland

    Acidum alendronicum; cholecalciferol (vitamin D3)

    Organon

    Dosage Form : Tabl

    Dosage Strength : 70/2800

    Packaging :

    Brand Name : Fosavance weekly tablets

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Switzerland

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Brand Name : Fosavance weekly tab...

    U.S.A
    American Thoracic Society
    Not Confirmed
    arrow

    Brand Name : Fosavance weekly tab...

    U.S.A
    arrow
    American Thoracic Society
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : Switzerland

    Acidum alendronicum; cholecalciferol (vitamin D3)

    Organon

    Dosage Form : Tabl

    Dosage Strength : 70/5600

    Packaging :

    Brand Name : Fosavance weekly tablets

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Switzerland

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Brand Name : Fosavance weekly tab...

    U.S.A
    American Thoracic Society
    Not Confirmed
    arrow

    Brand Name : Fosavance weekly tab...

    U.S.A
    arrow
    American Thoracic Society
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : Switzerland

    Acidum alendronicum; cholecalciferol (vitamin D3)

    Organon

    Dosage Form : Tabl

    Dosage Strength : 70/5600

    Packaging :

    Brand Name : Fosavance weekly tablets

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Switzerland

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Brand Name : Famax

    U.S.A
    American Thoracic Society
    Not Confirmed
    arrow

    Brand Name : Famax

    U.S.A
    arrow
    American Thoracic Society
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : Italy

    Alendronate Sodium Trihydrate

    Merck & Co

    Dosage Form : Alendronic Acid 70Mg 4 Units' ...

    Dosage Strength : 4 CPR 70 mg

    Packaging :

    Brand Name : Famax

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Italy

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Brand Name : Famax

    U.S.A
    American Thoracic Society
    Not Confirmed
    arrow

    Brand Name : Famax

    U.S.A
    arrow
    American Thoracic Society
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : Italy

    Alendronate Sodium Trihydrate

    Merck & Co

    Dosage Form : Alendronic Acid 10Mg 14 Joined...

    Dosage Strength : 14 CPR 10 mg

    Packaging :

    Brand Name : Famax

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Italy

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Services

    Upload your portfolio for free, ask us

    API & Drug Product Development

    Click here to discover the service providers for API & Drug Product Development

    Excipients

    Click here to find the perfect excipient manufacturers by their capabilities

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Merck & Co and get a quotation

    Merck & Co is a supplier offers 149 products (APIs, Excipients or Intermediates).

    Find a price of Betamethasone bulk with DMF, CEP offered by Merck & Co

    Find a price of Betamethasone bulk with CEP offered by Merck & Co

    Find a price of Ivermectin bulk with CEP offered by Merck & Co

    Find a price of Loratadine bulk with CEP offered by Merck & Co

    Find a price of 2-Methoxyestradiol bulk offered by Merck & Co

    Find a price of 5-N,N-Dibenzylglycyl-Salicylamide bulk offered by Merck & Co

    Find a price of Arprinocid bulk offered by Merck & Co

    Find a price of Brompheniramine Maleate bulk offered by Merck & Co

    Find a price of Butorphanol Tartrate bulk offered by Merck & Co

    Find a price of CAS 50-28-2 bulk offered by Merck & Co

    Find a price of Chlorpheniramine Maleate bulk offered by Merck & Co

    Find a price of Conjugated Estrogens bulk offered by Merck & Co

    Find a price of Corticosterone bulk offered by Merck & Co

    Find a price of Danazol bulk offered by Merck & Co

    Find a price of Desogestrel bulk offered by Merck & Co

    Find a price of Dexamethasone bulk offered by Merck & Co

    Find a price of Dexamethasone Sodium Phosphate bulk offered by Merck & Co

    Find a price of Dexbrompheniramine Maleate bulk offered by Merck & Co

    Find a price of Dexchloropheniramine Maleate bulk offered by Merck & Co

    Find a price of Diethylstilbestrol bulk offered by Merck & Co

    Find a price of Diflunisal bulk offered by Merck & Co

    Find a price of Dihydrotestosterone bulk offered by Merck & Co

    Find a price of Diltiazem bulk offered by Merck & Co

    Find a price of Droperidol bulk offered by Merck & Co

    Find a price of Edrophonium Chloride bulk offered by Merck & Co

    Find a price of Enalapril Maleate bulk offered by Merck & Co

    Find a price of Estradiol bulk offered by Merck & Co

    Find a price of Estriol bulk offered by Merck & Co

    Find a price of Estrovarin bulk offered by Merck & Co

    Find a price of Ethinyl Estradiol bulk offered by Merck & Co

    Find a price of Fentanyl Citrate bulk offered by Merck & Co

    Find a price of Fluphenazine Decanoate bulk offered by Merck & Co

    Find a price of Guaiazulene bulk offered by Merck & Co

    Find a price of Heparin Sodium bulk offered by Merck & Co

    Find a price of Hyaluronic Acid bulk offered by Merck & Co

    Find a price of Imipramine Hydrochloride bulk offered by Merck & Co

    Find a price of Lovastatin bulk offered by Merck & Co

    Find a price of Medroxyprogesterone Acetate bulk offered by Merck & Co

    Find a price of Megestrol Acetate bulk offered by Merck & Co

    Find a price of Mestranol bulk offered by Merck & Co

    Find a price of Mk-6240 bulk offered by Merck & Co

    Find a price of Mk2048 bulk offered by Merck & Co

    Find a price of Nalbuphine Hydrochloride bulk offered by Merck & Co

    Find a price of Nalmefene Hydrochloride bulk offered by Merck & Co

    Find a price of Naltrexone bulk offered by Merck & Co

    Find a price of Neomycin Sulfate bulk offered by Merck & Co

    Find a price of Norandrostenedione bulk offered by Merck & Co

    Find a price of Norethisterone bulk offered by Merck & Co

    Find a price of Norethisterone Acetate bulk offered by Merck & Co

    Find a price of Norgestimate bulk offered by Merck & Co

    Find a price of Omeprazole Magnesium bulk offered by Merck & Co

    Find a price of Oxandrolone bulk offered by Merck & Co

    Find a price of Oxytocin bulk offered by Merck & Co

    Find a price of Pheniramine Maleate bulk offered by Merck & Co

    Find a price of Pimozide bulk offered by Merck & Co

    Find a price of Prasterone Acetate bulk offered by Merck & Co

    Find a price of Prednisolone Sodium Phosphate bulk offered by Merck & Co

    Find a price of Prochlorperazine Edisylate bulk offered by Merck & Co

    Find a price of Promethazine Hydrochloride bulk offered by Merck & Co

    Find a price of Pyridostigmine bulk offered by Merck & Co

    Find a price of Testosterone Propionate bulk offered by Merck & Co

    Find a price of Thiabendazole bulk offered by Merck & Co

    Find a price of Thiamine Disulfide bulk offered by Merck & Co

    Find a price of Tibolone bulk offered by Merck & Co

    Find a price of Tubocurarine Chloride bulk offered by Merck & Co

    Find a price of Urofollitropin bulk offered by Merck & Co

    Find a price of Vitamin B12 bulk offered by Merck & Co

    Find a price of L-651,392-00N,4-BROMO-2,7-DIMETHOXY-3H-PHENOTHIAZIN-3-ONE bulk offered by Merck & Co

    Find a price of 1-METHYL-1-(B-CHLOROETHYL) ETHYLENIMONIUM PICRYSULFONATE bulk offered by Merck & Co

    Find a price of BULK FORM OF DRUG PRODUCT L-590,153 PROCESSED RAHWAY, N.J. FACILITIES bulk offered by Merck & Co

    Find a price of MANUF, CONTROL FACILITIES PROCEDURES FOR ALBANY, GA. PLANT bulk offered by Merck & Co

    Find a price of MERCK bulk offered by Merck & Co

    Find a price of NORGESTOMET bulk offered by Merck & Co

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN LE PUY CEDEX, FRANCE. bulk offered by Merck & Co

    Find a price of FACILS., METHODS & CONTROLS FOR PROCESSING & PACKAGING OF DRUG PRODS. bulk offered by Merck & Co

    Find a price of TECHNETIUM Tc 99M POLYPHOSPHATE KIT bulk offered by Merck & Co

    Find a price of MANUF&CONTROL FACILITIES&PROCEDURES AT SUBSIDIARY PLANT BARCELONETA,PR bulk offered by Merck & Co

    Find a price of J-107088 bulk offered by Merck & Co

    Find a price of FACILITIES AND OPERATING PROCEDURES IN CLERMONT-FERRAND,FRANCE bulk offered by Merck & Co

    Find a price of AMPROLIUM IN CHICKENS (VET) bulk offered by Merck & Co

    Find a price of AMPROL SUPER PLUS (AMPROLIUM & ETHOPABATE) (VET) bulk offered by Merck & Co

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN HOBBESDON, HERFORDSHIRE, ENGLAND. bulk offered by Merck & Co

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN WILSON, NORTH CAROLINA. bulk offered by Merck & Co

    Find a price of MANUF.CONTROL,FACILITIES &PROCEDURES-AT RAHWAY, NJ PLANT bulk offered by Merck & Co

    Find a price of PREPARATION OF TEN STABLE ISOTOPE-LABELLED COMPOUNDS bulk offered by Merck & Co

    Find a price of STERILE DILUENT bulk offered by Merck & Co

    Find a price of FACILITY AND PROCEDURES IN OSS, THE NETHERLANDS - MOLENSTRAAT 110 bulk offered by Merck & Co

    Find a price of MK-4176 DRUG SUBSTANCE bulk offered by Merck & Co

    Find a price of NITROGEN MUSTARDS bulk offered by Merck & Co

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES. bulk offered by Merck & Co

    Find a price of MANUF. & CONTROL,FACILITIES & PROCEDURES-FOR ELKTON, VA. PLANT bulk offered by Merck & Co

    Find a price of CORTATE (DESOXYCORTICOSTERONE ACETATE) bulk offered by Merck & Co

    Find a price of AMPROLIUM MEDICATED FEED -(3-NITRO-4-HYDROXYPHENYLARSONIC ACID) (VET) bulk offered by Merck & Co

    Find a price of PRO-STREP CRUMBLES (VET) bulk offered by Merck & Co

    Find a price of HADACIDIN SOD. DIHYDRATE (NSC 521778) & HADACIDIN POTASS. NSC 72962 bulk offered by Merck & Co

    Find a price of MANUF. CONTROL FACILITIES & PROCEDURES FOR DANVILLE PA PLANT bulk offered by Merck & Co

    Find a price of RATHDRUM, COUNTY WICKLOW, IRELAND bulk offered by Merck & Co

    Find a price of PORCINE INSULIN HIGHLY PURIFIED bulk offered by Merck & Co

    Find a price of ORG 32489 RECOMBINANT FSH bulk offered by Merck & Co

    Find a price of HYDROCORT. 21-PHOSPHATE & NEOMYCIN SO4--OPTHAL. SOL. 0.5% & INJECT bulk offered by Merck & Co

    Find a price of MANUFACTURE AND CONTROL bulk offered by Merck & Co

    Find a price of PROCESS $ CONTROL DATE CONCERNING MANUFACTURE OF 2-ACETYLAMINA ETC. bulk offered by Merck & Co

    Find a price of L-000825058 bulk offered by Merck & Co

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN OKAZAKI CITY, JAPAN. bulk offered by Merck & Co

    Find a price of PRO-STREP IN SWINE (VET) bulk offered by Merck & Co

    Find a price of Alendronate Sodium bulk offered by Merck & Co

    Find a price of Aprepitant bulk offered by Merck & Co

    Find a price of Avobenzona bulk offered by Merck & Co

    Find a price of Betamethasone Sodium Phosphate bulk offered by Merck & Co

    Find a price of Boceprevir bulk offered by Merck & Co

    Find a price of Boric Acid bulk offered by Merck & Co

    Find a price of CAS 532-40-1 bulk offered by Merck & Co

    Find a price of CAS 654671-77-9 bulk offered by Merck & Co

    Find a price of Caspofungin bulk offered by Merck & Co

    Find a price of Choriogonadotropin Alfa bulk offered by Merck & Co

    Find a price of Cilastatin bulk offered by Merck & Co

    Find a price of Cilastatin Sodium bulk offered by Merck & Co

    Find a price of Cocarboxylase bulk offered by Merck & Co

    Find a price of Cocarboxylase Tetrahydrate bulk offered by Merck & Co

    Find a price of Desloratadine bulk offered by Merck & Co

    Find a price of Dexketoprofen Trometamol bulk offered by Merck & Co

    Find a price of Doravirine bulk offered by Merck & Co

    Find a price of Elbasvir bulk offered by Merck & Co

    Find a price of Ensulizole bulk offered by Merck & Co

    Find a price of Ertapenem Sodium bulk offered by Merck & Co

    Find a price of Ezetimibe bulk offered by Merck & Co

    Find a price of Fenbendazole bulk offered by Merck & Co

    Find a price of Florfenicol bulk offered by Merck & Co

    Find a price of Flunixin Meglumine bulk offered by Merck & Co

    Find a price of Gentamicin Sulfate bulk offered by Merck & Co

    Find a price of Grazoprevir bulk offered by Merck & Co

    Find a price of Imipenem bulk offered by Merck & Co

    Find a price of Letermovir bulk offered by Merck & Co

    Find a price of Loratadine bulk offered by Merck & Co

    Find a price of Meglumine bulk offered by Merck & Co

    Find a price of Metformin bulk offered by Merck & Co

    Find a price of Milbemycin Oxime bulk offered by Merck & Co

    Find a price of Montelukast Sodium bulk offered by Merck & Co

    Find a price of Posaconazole bulk offered by Merck & Co

    Find a price of Potassium Phosphate bulk offered by Merck & Co

    Find a price of Raltegravir Potassium bulk offered by Merck & Co

    Find a price of Rocuronium Bromide bulk offered by Merck & Co

    Find a price of Simvastatin bulk offered by Merck & Co

    Find a price of Sitagliptin Phosphate bulk offered by Merck & Co

    Find a price of Sodium Fluoride bulk offered by Merck & Co

    Find a price of Suvorexant bulk offered by Merck & Co

    Find a price of Trisodium Citrate Dihydrate bulk offered by Merck & Co

    Find a price of Zinc Oxide bulk offered by Merck & Co

    Find a price of LUPROSTIOL bulk offered by Merck & Co

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search